Introduction
Autism is a neurodevelopmental disorder characterized by impaired social interaction and communication, and a restricted range of interests and activities, with onset during the first three years of life. Autism spectrum disorders (ASDs), which include autism, pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger syndrome, have a typical male preponderance and their estimated prevalence is 6/1000 ( ). ASDs are etiologically heterogeneous, with an underlying genetic disorder identified in 10 higher-resolution whole-genome analyses using array-based technologies have revealed genomic imbalances in at least 10 of cases (
).
Duplications of the 15q11-q13 region are the most frequently reported chromosomal aberration in individuals with ASDs ( ). This 8 region includes the Prader-Willi syndrome/Angelman syndrome (PWS/AS) critical region, which is subject to genomic imprinting. Most duplications of this interval are caused by supernumerary chromosomes formed by the inverted duplication of proximal 15q, known as isodicentric chromosome 15 idic( ) ( ). Interstitial duplications of this region are less frequent ( ), but many cases have been reported in association with autism ( , , ). The majority of cases are associated with maternally-derived duplications, whereas 10 13 15 -17 paternal inheritance usually leads to normal phenotypes ( , , , ).
10 15 16 18 Deletions or methylation abnormalities of chromosome 15 result in either Prader-Willi syndrome or Angelman syndrome, depending on whether they arise on the paternal or maternal chromosome. Both syndromes have been described in patients with ASD or autistic behavior, and recent studies estimate that over half of the patients with Angelman syndrome have ASD ( ).
-21
The genomic instability of proximal chromosome 15 is mediated by low-copy repeats, resulting in five recurrent breakpoints (BP) involved in deletions, duplications and idic( ) ( ). The deletions involve either the proximal BP1 or BP2 and share the same distal 15 22 breakpoint (BP3), whereas the duplications can extend more distally to BP4 or BP5 ( ). The critical region involved in PWS/AS and Fig. 1 the 15q11-q13 duplication syndrome lies between BP2 and BP3. Nonallelic homologous recombination between flanking low-copy repeats is also involved in other microdeletion/microduplication syndromes associated with mental retardation and ASDs, including 17p11.2,
22q11.2 and 7q11.23 ( ). 23
Although the frequency of 15q11-q13 duplications in autism is widely assumed to be 1 3 , this estimate is based on two small %-% series of patients. In a study of 140 subjects with autism, two were found with a maternal interstitial duplication of 15q11-q13 ( ). 24
Schroer studied 100 patients with autism and identified two idic( ), one maternally-derived interstitial duplication and one maternal et al. 15
deletion ( ). The small numbers of patients studied makes it difficult to draw conclusions on the real contribution of such duplications to 10
ASD. The prevalence of proximal 15q deletions in ASDs is also unknown. Recent genome-wide studies of copy number variants in large ASD samples included an unknown proportion of patients who had been previously screened for chromosomal abnormalities and 15q11-q13 rearrangements (and excluded if positive), thus precluding the estimation of prevalence ( , ).
The aim of this study was to assess the frequency of 15q11-q13 abnormalities in 522 individuals with ASDs. We screened the PWS/AS region for gene dosage alterations using multiplex ligation-dependent probe amplification (MLPA) and quantitative microsatellite analysis. In addition, we searched for methylation abnormalities of chromosome 15, including uniparental disomies and imprinting center defects, using methylation-sensitive MLPA ( ). Epigenetic defects have long been suspected in autism ( , ), but 25 26 27 no systematic screening of methylation abnormalities of chromosome 15 had been performed.
Methods and Materials

Patients
A total of 522 patients with ASD belonging to 430 families were studied. Subjects were recruited by the Paris Autism Research
International Sibpair (PARIS) study at specialized clinical centers in Europe and the United States. The patients included 393 males and 129 females (ratio 3:1), with a mean age at the last evaluation of 11 7.5 years (range 2.5 43); 187 belonged to 95 multiplex families (with ± -two or more affected siblings) and 335 were sporadic cases. All patients were evaluated by psychiatrists or child neurologists and diagnosed based on clinical evaluation and DSM-IV criteria. Patients were assessed with the Autism Diagnostic Interview-Revised (ADI-R) ( ) and the Asperger Syndrome Diagnostic Interview ( ). Four-hundred seventy-two individuals met criteria for autism, 26 28 29 for Asperger syndrome and 24 for PDD-NOS. Three-hundred fifty-six patients (68 ) had mental retardation, 261 (50 ) had very limited % % or no language, and 66 (13 ) had a history of epilepsy. Most patients were Caucasian (89 ). Laboratory tests included karyotype, fragile % % X and metabolic screening; brain imaging and EEG were performed when possible. Patients with known genetic disorders were excluded.
Chromosome analysis identified one female harboring a supernumerary isodicentric derivative chromosome 15; we report here the cytogenetic, molecular and phenotypic characterization of this patient. No other patients had been excluded from the sample prior to this 3 13 study because of cytogenetic abnormalities of chromosome 15q11-q13. The study was approved by the research ethics boards of the collaborating institutions. Informed consent was obtained from all families participating in the study.
Multiplex ligation-dependent probe amplification (MLPA)
Patients were screened for rearrangements involving the 15q11-q13 region using the ME028 PWS/AS and/or the P064 MR1 MLPA 
Quantitative microsatellite analysis
Five microsatellite markers in the 15q11-q13 region (D15S11, D15S817, D15S1513, D15S1019 and D15S815) were used to assess DNA copy number and follow the transmission of the alleles ( ). PCR conditions (in particular the number of PCR cycles) were set Fig. 1 up so as to perform allele dosage. PCR products were quantified on an ABI3730 sequencer (Applied Biosystems).
Results
Five quantitative assays using microsatellites were used to screen the 15q11-q13 region in 217 patients. However, analysis of the markers D15S11 and D15S817 revealed three alleles in 10 of patients, a proportion comparable to that in a control population, indicating % that this region is duplicated in healthy individuals. We therefore decided to screen all patients using MLPA.
Overall, we identified four patients with 15q11-q13 abnormalities considered to be pathogenic: an idic( ), an interstitial duplication, 15 a deletion and an uniparental disomy. Their clinical features are summarized in and are described in more detail in Supplement 1. Table 1 Supernumerary isodicentric chromosome 15
Patient 1 had an idic( ) revealed by the karyotype and confirmed by FISH, described as 47,XX, mar.ish der( )(D15Z1 , SNRPN 15
Microsatellite analysis of the patient and her parents showed that she had a copy number gain of showed a normal copy number ( ). These findings suggest that the distal breakpoint of the idic( ) lies between BP4 and BP5, in Fig. 2E 15 agreement with the microsatellite results. The probeb showed an increase in dosage to the hexasomy range, suggesting a complex KLF13 rearrangement at the site of the breakpoint. We could not differentiate between one or two breakpoints, because of the inability to estimate the precise copy number of individual probes on the basis of qPCR ( ).
Fig. 2E
Interstitial 15q11-q13 duplication Patient 2 had three alleles for both D15S11 and D15S817. He was homozygous for D15S1513 and D15S1019, which were therefore uninformative, and heterozygous without imbalance for D15S815, located between BP3 and BP4 (not shown). MLPA confirmed the presence of a ~4.6 Mb duplication between BP2 and BP3, corresponding to the critical region deleted in PWS/AS ( ). Fig. 4 Methylation-sensitive MLPA showed normal dosage of the methylated maternal probes in and indicating that the SNRPN NDN, duplication was paternally derived ( ). MLPA of the parents showed that the duplication was inherited from the unaffected father (  Fig. 3 ). Methylation analysis of the father showed a paternal origin of the duplication (not shown), but no DNA was available from the Fig. 4 grandfather to determine if the duplication was inherited or had arisen FISH using the UBE3A probe confirmed the presence of de novo.
an increased signal in Patient 2 (not shown).
Angelman syndrome: deletion and uniparental disomy
Patients 3 and 4 had only one allele for three markers located in the PWS/AS region (D15S11, D15S817 and D15S1513), suggesting that they could be either homozygous or deleted in this region ( ). Examination of the parents haplotypes showed that both patients Fig. 5A had only one allele from the father and none from the mother ( ). MLPA confirmed that Patient 3 had a maternal class I deletion Fig. 5A extending ~5.6 Mb from BP1 to BP3 that arose ( , ). FISH with probe D15S10 confirmed the deletion (not shown). In de novo Fig. 3 5C Patient 4, MLPA showed a normal copy number of the 15q11-q13 region ( ) but methylation-sensitive MLPA revealed a complete Fig. 5C absence of maternal methylated DNA sequences, indicating a paternal uniparental disomy ( ). FISH showed normal hybridization of Fig. 3 probes SNRPN and D15S10 (not shown), consistent with the diagnosis of uniparental disomy.
Abnormal copy number of the BP1-BP2 region
MLPA also detected three patients with a deletion (Patients 5, 6 and 7) and two with a duplication (Patients 8 and 9) of the BP1-BP2 interval, which spans 254 kb and encompasses four genes, and ( ). All the rearrangements were TUBGCP5, CYFIP1, NIPA1, NIPA2 Fig. 1 inherited from parents who were unaffected or had unrelated psychiatric disorders ( ). Table 1 The cytoplasmic FMR1 interacting protein 1 (CYFIP1) interacts with FMRP, encoded by the fragile X mental retardation 1 (FMR1) gene. Since fragile X syndrome is often associated with autism, constitutes a candidate gene for autism. In order to test the CYFIP1 possibility that point mutations in this gene, either inherited from the other parent or could lead to autism in association with the de novo, BP1-BP2 imbalance, we sequenced the whole coding region of in the five probands with abnormal dosage of this region. In CYFIP1 
Other deletions or sequence variants considered non pathogenic
We identified one patient with a paternally-inherited deletion of exon 1 in one of the transcript variants of the gene. Because UBE3A the deleted exon is noncoding and is maternally expressed, this genomic imbalance is unlikely to have clinical consequences. In UBE3A another patient, MLPA showed an apparent deletion of one probe in the promoter/exon1 region, due to a maternally-inherited SNRPN nucleotide change previously reported as a rare neutral variant (see Supplement 1 for further details on these two patients).
Methylation abnormalities
Aside from the uniparental disomy identified in Patient 4, no other methylation abnormalities were observed in 331 patients screened with methylation-sensitive MLPA. In the remaining subjects, uniparental disomy was ruled out with microsatellite analysis.
Discussion
In this study, we found a pathogenic rearrangement of the 15q11-q13 region in 4 out of 430 families. Thus, proximal 15q abnormalities, including deletions, supernumerary isodicentric chromosomes and interstitial duplications, are found in about 1 of patients microsatellites predicted an atypical distal breakpoint between BP4 and BP5. A similar breakpoint was reported in a patient with an idic (15 ) , between D15S1013 andD S1031 ( ). and language, varying degrees of mental retardation, autism or autistic features, motor coordination difficulties, and mild or no dysmorphic features ( ). The phenotype is highly variable, even among members of the same family carrying identical rearrangements ( ) and can 16 16 in some cases manifest as developmental language disorder and dyspraxia, without autism ( ). The clinical findings in Patient 2 are 35 similar to those described in patients with maternal 15q11-q13 duplications, although he lacks the hypotonia, motor coordination problems and joint laxity observed in other cases ( , ).
17
The frequency of 15q11-q13 interstitial duplications is estimated at 1:600 individuals referred with developmental delay ( ). 36
Although previous studies in small samples of patients had suggested a frequency of 1 for maternally-derived interstitial duplications in % autism ( , ), we did not detect any such cases in our sample but found one patient harboring a paternal 15q11-q13 duplication. In 10 24 agreement with our findings, Bolton screened 181 patients with autism and found only one interstitial duplication of paternal origin ( et al. 15 may be underestimated because previous studies included an unknown proportion of subjects that had been screened for cytogenetic abnormalities prior to inclusion. It also should be noted that none of these studies were based on epidemiological samples and the possibility of ascertainment biases cannot be excluded.
Maternal versus paternal duplications
Interstitial duplications of 15q11-q13 of maternal origin are associated with developmental delay and/or autistic behavior, whereas paternally-derived duplications usually lead to a normal phenotype ( , , , ). However, as shown in , there have been at 10 15 16 18 Table 2 least six reports of paternal duplications encompassing the PWS/AS region associated with an abnormal phenotype, including mental retardation, delayed or absent speech, and ASD or autistic behavior ( ). In addition, two patients with an interstitial 15q11-q13 37 -41 triplication of paternal origin have been reported ( , ). Together with the patient with the paternal duplication described here, these 42 43 findings suggest that paternally-derived duplications may lead to phenotypic effects, including autism. Thus, there may be other genetic and/or environmental/epigenetic factors operating to modify the penetrance and expressivity of paternal duplications. Similar as yet unknown factors could come into play to modify the phenotypic expression of maternal 15q11-q13 duplications, which are also associated with a wide range of developmental problems and show marked clinical variability among members of the same family, including individuals who appear unaffected ( ). 16 It is interesting to note that several of the patients with paternally-inherited duplications or triplications described previously had
Prader-Willi syndrome-like features ( ) ( , , ), suggesting a role of paternally-expressed genes mapping within the PWS/AS Table 2 38 40 43 region (e.g., and in the phenotypic manifestations. Several recent studies have shown that MKRN3, MAGEL2, NDN, SNRPN-SNURF)
ASD is more prevalent in Prader-Willi syndrome patients than was previously thought ( ), in agreement with a contribution of 44 paternally-expressed genes to the ASD phenotype. Further research is needed to examine the effect of parental origin on phenotypic outcomes of 15q11-q13 duplications and their contribution to ASD. In particular, studies of gene expression in tissues from patients with paternal duplications may improve our understanding of the effect of these rearrangements on phenotype.
Angelman syndrome and ASD
The prevalence of Angelman syndrome is estimated at 1/12,000 ( ). this study, we identified two subjects with Angelman syndrome, one with a maternal deletion and the second with a uniparental disomy, for a ~0.5 frequency.
Because certain features of autism overlap with those seen in Angelman syndrome, including severe mental retardation, absence of speech or very limited language, epilepsy and/or abnormal EEG, and stereotyped behaviors, the diagnosis of Angelman syndrome may be overlooked in patients with ASD, as happened with our two patients. Although neither patient exhibited the classical phenotype, their clinical presentation is within the normal range of phenotypic variability observed in Angelman syndrome. In common with the majority of patients with Angelman, they exhibited severe cognitive impairment and limited or absent language, but had no ataxia or microcephaly, and seizures and unprovoked laughter (during infancy only) were observed only in one.
BP1-BP2 microdeletions/microduplications
We identified three deletions and two duplications of the region between BP1 and BP2, all inherited from unaffected parents. A BP1-BP2 deletion was reported recently in a boy with mental retardation, speech delay and neurological deficits, but the interpretation was complicated by the presence of the same deletion in the father, who also showed cognitive impairment ( ). Copy number gains and 47
losses of this region have also been identified in genome-wide array analyses of control individuals (Database of Genomic Variants, ), with a population frequency estimated at 1 ( ), suggesting that this may be a copy number http://projects.tcag.ca/variation/ % 48 polymorphism. In agreement with this interpretation, individuals carrying small idic( ) with extra copies of the four genes included in 15 the BP1-BP2 interval but that do not carry extra genomic material distal to BP2 are phenotypically normal ( ), suggesting that these 31 genes do not exert clinically significant dosage effects.
Nevertheless, it is interesting to note that and have been suggested to modulate the PWS/AS NIPA1, NIPA2, CYFIP1 TUBGCP5
phenotype. Angelman patients with class I deletions (including the BP1-BP2 interval) are more likely to meet criteria for autism and lack vocalizations compared with patients having smaller class II deletions ( ). Similarly, in Prader-Willi syndrome, class I deletions are 20 associated with more obsessive-compulsive behaviors and lower intellectual ability ( ), and mRNA levels of these four genes are 49
positively correlated with better behavioral outcomes ( ). More recently, BP1-BP2 deletions were shown to be significantly associated 50
with schizophrenia ( ), suggesting that these variants may increase risk for various neuropsychiatric phenotypes, albeit with low 51 penetrance and/or variable expressivity.
One of the genes situated in this interval, is particularly interesting in the context of ASD. CYFIP1 interacts with fragile X CYFIP1, mental retardation protein (FMRP) as well as with the Rho GTPase Rac1, which plays a role in the regulation of axonal migration and dendritic spine morphology. CYFIP1 has been proposed as a potential molecular link between fragile X syndrome and 15q11-13 duplication, since both disorders result in excess free CYFIP1 ( ). In order to test the possibility that the BP1-BP2 deletion unmasked a 52 recessive mutation on the other chromosome we sequenced as well as and genes encoding fragile CYFIP1, NIPA1, NIPA2, TUBGCP5, X-related proteins and in patients carrying BP1-BP2 deletions, identifying no mutations. Clearly, more research is (FMR1, FXR1 FXR2), required to determine the phenotype correlations of BP1-BP2 deletions and duplications and the role of , , and NIPA1 NIPA2 CYFIP1
, if any, in neurodevelopmental disorders. TUBGCP5
Conclusion
The present findings confirm that genetic abnormalities of the 15q11-q13 region are an important cause of ASD, accounting for approximately 1 of cases. Our results suggest that patients with ASD, particularly those with mental retardation, should be systematically 
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